Raising the Odds: How a Full-Stack Platform Unlocks Bigger, Better Opportunities

Ask a dozen R&D leaders what they expect from AI and you’ll get a dozen variations on the same theme: they’re ready to be convinced, but they want to see it work against more strategic problems. I agree with that instinct. The bar for impactful AI in drug development isn’t a neat demo; it’s shifting a critical decision that moves a pipeline forward — and doing it in a way you can defend to your team and regulators.

 

Here’s what I’ve learned: the only reliable way to get there is to treat AI as a full‑stack problem. Not a model bolted onto a dataset; not a report generator parked at the end of a workflow. The leaders pulling ahead are uniting three things in one place: proprietary data at scale, AI models and agents tuned (and fine-tuned) for the work, and compute infrastructure that works seamlessly with that data. That combination doesn’t just make tasks faster; it changes which questions you can ask, how often you can ask them, and how much trust you can put in the answers.

 

Why Data Comes First

 

The foundation is data — not in the abstract, but the kind that actually observes the world we’re trying to influence. In clinical development, the most difficult questions live exactly where historical datasets fall short: why a subgroup didn’t respond, how prior therapies shape outcomes, what comorbidities matter in the wild, which biomarkers differentiate responders. You don’t reason your way into those answers; you observe them across enough patients, treatments, and outcomes to see the pattern and, ideally, understand the cause-and-effect relationship. Trial data is critical, but it’s a narrow, controlled slice of reality. The missing context is real‑world information that can capture the complexity of biology with sufficient statistical power.

 

Even the best general-purpose models can’t conjure a signal that was never captured. That’s why models trained only on the internet, public corpora, and a project’s local files so often stall at the edge of what matters. To push past that boundary, you need datasets that are large and rich enough to reflect actual biology — and to keep reflecting it as it evolves over time.

 

Similarly, the best data alone doesn’t solve the problem. Once the corpus gets truly large, it isn’t practical to ship it around and hope teams layer AI on top. At hundreds of petabytes — the scale at which we operate at Tempus — the physics flip. You bring analyses and compute to the data, not the other way around, and you don’t stop at a single model. Instead, you orchestrate the right ensemble: frontier models for reasoning and planning; domain‑trained models that learned biology from multimodal, patient‑level data; and AI agents that can plan, call tools, and document their steps like a scientist. The advantage isn’t owning one “best” model; it’s routing each task to whatever delivers the best answer, and being able to re‑decide as the field evolves.

 

The Full-Stack Approach That Works

 

Here’s the stack that I’ve seen consistently deliver:
Real‑world data at scale

• Longitudinal, multimodal data — clinical, molecular, imaging, treatments, outcomes — de‑identified and linked at the patient level.
• Breadth for generalizability, depth for signal, and daily refreshes so yesterday’s analysis doesn’t run on last year’s evidence.

 

AI models and agents

• Frontier models excel at reasoning, summarizing, and planning, and their capabilities continue to expand at an unprecedented pace. A flexible system that works seamlessly with various frontier models — while pairing them with domain-trained models — grounds conclusions in biology and clinical practice.
• Agents act like reliable junior scientists: they plan multi‑step tasks, call the right tools, fetch cohorts, run analyses, and explain their work with provenance. They don’t just give an answer; they show how they got there.

 

Compute capacity — brought to the data

• High‑performance compute co‑located with the dataset, so you analyze where the evidence lives. No waiting for months‑long handoffs and transfers, and cohorts aren’t stale by the time you actually start the analysis.
• Secure, governed, and auditable by default: lineage for every result, policy enforcement, reproducibility, and isolation so teams can move fast without compromising trust.

 

When these three live together, the tempo changes and the pace of iteration accelerates. A workflow that used to require ten people and four months can compress into one that requires a single person and just a day’s work. That’s not a parlor trick; it’s compounded capacity. The same team can now test ten times more hypotheses, interrogate targets from more angles, and build far richer priors before committing to a path.

 

At the scale at which precision medicine operates, the cost of moving data isn’t just dollars; it’s time, risk, and staleness. Every transfer is an opportunity for drift, delays, and governance headaches.

Probability, Time, and the Right Patients

 

In our world, capacity converts into three kinds of value:

The right stack has the potential to scale these gains beyond individual teams and across the industry. Oncology sits near a 10% probability of success from Phase I to approval. I believe pushing toward 50% is within reach when you combine the right data, the right people, and the right AI — all iterating together, all the time.

 

What I’ve Seen Up Close

 

I’ve sat in reviews where a team cut a cohort, shipped it, waited weeks for it to land in a separate environment, then finally started analysis — only to discover they needed a different slice and started over. I’ve also seen the opposite: a scientist pivots from one cohort to another in an afternoon, runs orthogonal analyses overnight, and walks in the next morning with three hypotheses, two falsified, one worth pursuing. Same talent, same questions — different stack.

 

I’m often asked whether we should standardize on a single “workhorse” model. In my experience, that’s a trap. Models improve in different directions on different timelines. Yesterday’s best may be tomorrow’s second‑best for your task. Treat models like a team: specialists with clear roles, reviewed regularly. Hold them to the same standard you expect from people: show your work. In our field, trust isn’t a feeling; it’s a traceable lineage from answer to evidence with humans in the loop.

 

None of this matters if you can’t defend the output. An AI system in drug development must meet the scientific standard: it must reason, cite its sources, and remain auditable. That’s why Tempus Lens ties every result back to source records and shows its work. The goal isn’t blind faith in automation, but a disciplined partnership where AI does the repeatable heavy lifting and people do what they do best — ask better questions, interpret, and decide.

 

Bringing the Stack Together

 

If you want AI that can consistently advance your pipeline, I’d highly recommend leveraging a full-stack system rather than treating models as accessories to workflows. Equip great scientists with real‑world data, AI models and agents, and compute infrastructure in one place and let them iterate at unparalleled speed. That’s where skepticism turns into proof — not because a demo was slick, but because your team could translate data into insights that address the questions keeping you up at night.

 

The next generation of medicines will be built by teams that integrate the stack most completely, weaving great technology with great expertise to make the best decisions consistently. If you’re serious about increasing probability, compressing time, and getting therapies to the right patients, it’s time to bring all the ingredients together to supercharge the scientific process. Our patients are counting on it.

 

Book a demo to see what Tempus Lens can do for your programs.